Biblio Discovery — Demo Discovery Service

13 results for "Scott N. Gettinger"

Showing 1–13 · 0.24 seconds · RSS

  1. Journal Article

    Oncolytic virus immunotherapy: future prospects for oncology

    Junaid Raja; Johannes M. Ludwig; Scott N. Gettinger et al.

    Journal for ImmunoTherapy of Cancer, Vol. 6 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Background Immunotherapy is at the forefront of modern oncologic care. Various novel therapies have targeted all three layers of tumor biology: tumor, niche, and immune system with a range of promising results. One emerging class in both primary and salvage therapy is oncolytic viruses…

  2. Journal Article

    Immuno-thermal ablations – boosting the anticancer immune response

    Ryan Slovak; Johannes M. Ludwig; Scott N. Gettinger et al.

    Journal for ImmunoTherapy of Cancer, Vol. 5 No. 1 · 2017 · English · DOAJ Scopus

    Abstract The use of immunomodulation to treat malignancies has seen a recent explosion in interest. The therapeutic appeal of these treatments is far reaching, and many new applications continue to evolve. In particular, immune modulating drugs have the potential to enhance the systemic anticancer…

  3. Journal Article

    Cryotherapy for nodal metastasis in NSCLC with acquired resistance to immunotherapy

    Lucas C. Adam; Junaid Raja; Johannes M. Ludwig et al.

    Journal for ImmunoTherapy of Cancer, Vol. 6 No. 1 · 2018 · English · DOAJ Scopus

    Abstract Novel approaches with checkpoint inhibitors in immunotherapy continue to be essential in the treatment of non-small cell lung cancer (NSCLC). However, the low rate of primary response and the development of acquired resistance during the immunotherapy limit their long-term effectiveness…

  4. Journal Article

    Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung Cancer (SCLC)

    Daniel Carvajal-Hausdorf; Mehmet Altan; Vamsidhar Velcheti et al.

    Journal for ImmunoTherapy of Cancer, Vol. 7 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Background Small cell lung cancer (SCLC) accounts for 10–15% of all lung malignancies and its prognosis is dismal. Although early studies have shown promising clinical activity of immune checkpoint blockers, the immune composition and expression of potentially actionable immunostimulatory…

  5. Journal Article Full text

    Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆

    David Robert Spigel; David Vicente; Tudor–Eliade Ciuleanu et al.

    Annals of Oncology · 2021 · English · OpenAlex Scopus

    BACKGROUND: Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC. PATIENTS AND METHODS: CheckMate 331 is a randomized, open-label, phase III trial of nivolumab versus standard…

  6. Journal Article

    Brigatinib Versus Crizotinib in Advanced ALK Inhibitor–Naive ALK-Positive Non–Small Cell Lung Cancer: Second Interim Analysis of the Phase III ALTA-1L Trial

    D. Ross Camidge; Hye Ryun Kim; Myung‐Ju Ahn et al.

    Journal of Clinical Oncology · 2020 · English · OpenAlex Scopus

    PURPOSE Brigatinib, a next-generation anaplastic lymphoma kinase (ALK) inhibitor, demonstrated superior progression-free survival (PFS) and improved health-related quality of life (QoL) versus crizotinib in advanced ALK inhibitor–naive ALK-positive non–small cell lung cancer (NSCLC) at first…

  7. Journal Article Full text

    Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial

    D. Ross Camidge; Hye Ryun Kim; Myung‐Ju Ahn et al.

    Journal of Thoracic Oncology · 2021 · English · OpenAlex Scopus

    INTRODUCTION: In the phase 3 study entitled ALK in Lung cancer Trial of brigAtinib in 1st Line (ALTA-1L), which is a study of brigatinib in ALK inhibitor-naive advanced ALK-positive NSCLC, brigatinib exhibited superior progression-free survival (PFS) versus crizotinib in the two planned interim…

  8. Journal Article

    Brief Report: Safety and Antitumor Activity of Alectinib Plus Atezolizumab From a Phase 1b Study in Advanced ALK-Positive NSCLC

    Dong-Wan Kim, MD, PhD; Shirish Gadgeel, MD; Scott N. Gettinger, MD et al.

    JTO Clinical and Research Reports, Vol. 3 No. 8 · 2022 · English · DOAJ Scopus

    Introduction: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. Methods: Adults with treatment-naive, stage IIIB/IV, or recurrent ALK-positive NSCLC…

  9. Journal Article Full text

    Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non–Small-Cell Lung Cancer

    Hossein Borghaei; Scott N. Gettinger; Everett E. Vokes et al.

    Journal of Clinical Oncology · 2021 · English · OpenAlex Scopus

    PURPOSE: Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxel in patients with previously treated…

  10. Journal Article Full text

    NCCN Guidelines Insights: Non–Small Cell Lung Cancer, Version 2.2021

    David S. Ettinger; Douglas E. Wood; Dara L. Aisner et al.

    Journal of the National Comprehensive Cancer Network · 2021 · English · OpenAlex Scopus

    The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer (NSCLC) address all aspects of management for NSCLC. These NCCN Guidelines Insights focus on recent updates to the NCCN Guidelines regarding targeted therapies, immunotherapies, and their respective…

  11. Journal Article Full text

    NCCN Guidelines® Insights: Non–Small Cell Lung Cancer, Version 2.2023

    David S. Ettinger; Douglas E. Wood; Dara L. Aisner et al.

    Journal of the National Comprehensive Cancer Network · 2023 · English · OpenAlex Scopus

    The NCCN Guidelines for Non-Small Cell Lung Cancer (NSCLC) provide recommendations for management of disease in patients with NSCLC. These NCCN Guidelines Insights focus on neoadjuvant and adjuvant (also known as perioperative) systemic therapy options for eligible patients with resectable NSCLC.

  12. Journal Article

    Long-Term Efficacy and Safety of Brigatinib in Crizotinib-Refractory ALK+ NSCLC: Final Results of the Phase 1/2 and Randomized Phase 2 (ALTA) Trials

    Scott N. Gettinger, MD; Rudolf M. Huber, MD, PhD; Dong-Wan Kim, MD, PhD et al.

    JTO Clinical and Research Reports, Vol. 3 No. 9 · 2022 · English · DOAJ Scopus

    Introduction: We report brigatinib long-term efficacy and safety from phase 1/2 and phase 2 (ALTA) trials in ALK–rearrangement positive (ALK+) NSCLC. Methods: The phase 1/2 study evaluated brigatinib 30 to 300 mg/d in patients with advanced malignancies. ALTA randomized patients with…